Head-to-head evidence
Lorlatinib vs XZP-3621
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK / ROS1 · full Non-Small Cell Lung Cancer pipeline
Lorlatinib
Marketed by Pfizer
NCT01970865 · Phase 1/2 · completed
This was an open-label, non-randomized, single-arm study with no concurrent control group, despite enrolling 364 patients across dose-escalation and expansion cohorts. The primary phase 2 endpoint was objective response rate by RECIST v1.1, a clinical response measure; response rates were reported descriptively, but there was no randomized comparator or blinding, so the results cannot establish comparative efficacy and are best interpreted as uncontrolled evidence.
Next expected readout: December 2026 · NCT05059522 (registry estimate)
XZP-3621
Developed by Xuanzhu Biopharmaceutical
NCT05204628 · Phase 3 · status unknown
Patients were randomly assigned to XZP-3621 or crizotinib, but the study is open-label rather than blinded, which is a weaker design even though it measures a hard clinical outcome, progression-free survival, against an active standard-of-care comparator. Results have not been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lorlatinib's landscape · XZP-3621's landscape